Observational studyCurrent cancer drug targets2025

Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50.

Xiangyu Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.